EyePoint, Inc. (EYPT) Stock
4 of the hedge funds AlphaScala tracks reported EYPT in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Citadel's at $28.28M. Company insiders reported 1 open-market buy and 0 sales on SEC Form 4 in the 90 days to Oct 21, 2026.
Which hedge funds own EYPT?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Citadel Ken Griffin | 1.98M | $28.28M | +4% |
| Millennium Management Israel Englander | 500K | $7.15M | +5% |
| Point72 Steve Cohen | 49K | $694.6K | NEW |
| Marshall Wace | 24K | $342.3K | -85% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are EyePoint, Inc. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Aug 18, 26 | Zaderej Karen L. | Director | BUY | 10.6K | $52K |
SEC Form 4 filings as of Oct 21, 2026
See cluster-buy signals across all tickers →EYPT price chart
Powered by TradingViewWhat does EyePoint, Inc. do?
EyePoint Pharmaceuticals Inc. is a specialty biopharmaceutical company focused on developing and commercializing innovative ophthalmic products. Its primary purpose is to treat serious eye disorders, particularly targeting diseases like wet age-related macular degeneration (AMD), diabetic macular edema, and retinal vein occlusion. EyePoint's unique approach leverages drug delivery technologies which offer sustained-release treatments, enhancing patient outcomes by providing consistent therapeutic levels over extended periods. The company operates within the biotechnology and healthcare sectors, impacting the pharmaceutical landscape by addressing unmet medical needs in ophthalmology. EyePoint Pharmaceuticals plays a significant role in the market through collaborations with leading eye care companies, advancing therapeutic research and expanding access to novel solutions for visual impairment. Based in Watertown, Massachusetts, the company continues to innovate and lead in the field of ocular drug development, contributing to the advancement of vision-related healthcare on a global scale.